Unleashing PBPK Modeling Potential in Pediatric Drug Development

This review aims to delineate the framework of pediatric physiologically based pharmacokinetic (PBPK) modeling, highlight pertinent guidelines, and examine its current applications and future potential in pediatric drug development.

Pediatric PBPK modeling has emerged as a critical tool by integrating drug property data with developmental physiology, thereby enhancing drug development for children. Regulatory agencies have acknowledged its significance, issuing various guidance documents that promote its use. Researchers and pharmaceutical developers are continually refining pediatric PBPK models to address the unique challenges of pediatric pharmacotherapy. Advances include improved model accuracy and predictive capabilities, which are instrumental in bridging gaps in pediatric pharmacokinetics and pharmacodynamics. Recent studies demonstrate that PBPK models are effective in predicting drug behavior in pediatric populations, thus facilitating safer and more effective dosing regimens.

With ongoing technological advancements and increasing data availability, PBPK models are set to play a pivotal role in pediatric drug development. Future efforts will likely focus on deepening the understanding of pediatric pharmacology and expanding the integration of PBPK modeling with other modeling approaches and technologies. These advancements will significantly enhance the utility of pediatric PBPK models, offering numerous opportunities to improve pediatric drug development.

This article does not contain original data from any clinical trials.